JP2023529845A5 - - Google Patents
Info
- Publication number
- JP2023529845A5 JP2023529845A5 JP2022574480A JP2022574480A JP2023529845A5 JP 2023529845 A5 JP2023529845 A5 JP 2023529845A5 JP 2022574480 A JP2022574480 A JP 2022574480A JP 2022574480 A JP2022574480 A JP 2022574480A JP 2023529845 A5 JP2023529845 A5 JP 2023529845A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- pharmaceutically acceptable
- eye disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020901858A AU2020901858A0 (en) | 2020-06-05 | Compounds and Methods for the Treatment of Eye Disorders | |
| AU2020901856 | 2020-06-05 | ||
| AU2020901858 | 2020-06-05 | ||
| AU2020901856A AU2020901856A0 (en) | 2020-06-05 | Compounds and Methods for the Treatment of Eye Disorders | |
| PCT/US2021/035749 WO2021247900A1 (en) | 2020-06-05 | 2021-06-03 | Compounds and methods for the treatment of eye disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529845A JP2023529845A (ja) | 2023-07-12 |
| JP2023529845A5 true JP2023529845A5 (https=) | 2024-05-15 |
Family
ID=78829970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574480A Pending JP2023529845A (ja) | 2020-06-05 | 2021-06-03 | 眼の障害の治療のための化合物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230270703A1 (https=) |
| EP (1) | EP4161527A4 (https=) |
| JP (1) | JP2023529845A (https=) |
| KR (1) | KR20230024331A (https=) |
| CN (1) | CN116033901A (https=) |
| AU (1) | AU2021284380A1 (https=) |
| BR (1) | BR112022024728A2 (https=) |
| CA (1) | CA3185849A1 (https=) |
| IL (1) | IL298733A (https=) |
| MX (1) | MX2022015327A (https=) |
| WO (2) | WO2021247900A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023018314A2 (pt) * | 2021-03-17 | 2023-10-31 | Occurx Pty Ltd | Compostos para o tratamento de distúrbios e sais e polimorfos dos mesmos |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6339814A (ja) * | 1986-08-01 | 1988-02-20 | Teisan Seiyaku Kk | トラニラストの経口用持続性製剤 |
| KR19990082523A (ko) * | 1996-02-15 | 1999-11-25 | 간자와 무츠와 | 혈관생성 억제제 |
| JPH09278653A (ja) * | 1996-04-05 | 1997-10-28 | Santen Pharmaceut Co Ltd | 網膜疾患治療剤 |
| CN1252718A (zh) * | 1997-04-18 | 2000-05-10 | 橘生药品工业株式会社 | 预防或治疗与视网膜色素上皮细胞过度增殖相关的疾病的药剂 |
| ATE526041T1 (de) * | 2001-12-11 | 2011-10-15 | Fibrogen Inc | Verfahren zur hemmung okularer vorgänge |
| NZ592039A (en) * | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| ES2830024T3 (es) * | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
| JP2011006406A (ja) * | 2009-05-29 | 2011-01-13 | Santen Pharmaceut Co Ltd | トラニラストを含有する網膜疾患の予防または治療剤 |
| NZ609144A (en) * | 2010-11-24 | 2014-08-29 | Occurx Pty Ltd | Methods of treating eye diseases associated with inflammation and vascular proliferation |
| US10780070B2 (en) * | 2013-10-18 | 2020-09-22 | The Schepens Eye Research Institute, Inc. | Alpha-aminoadipate for treatment of vision loss and restoring sight |
-
2021
- 2021-06-03 EP EP21818477.8A patent/EP4161527A4/en active Pending
- 2021-06-03 AU AU2021284380A patent/AU2021284380A1/en active Pending
- 2021-06-03 JP JP2022574480A patent/JP2023529845A/ja active Pending
- 2021-06-03 CN CN202180056862.4A patent/CN116033901A/zh active Pending
- 2021-06-03 MX MX2022015327A patent/MX2022015327A/es unknown
- 2021-06-03 CA CA3185849A patent/CA3185849A1/en active Pending
- 2021-06-03 KR KR1020237000380A patent/KR20230024331A/ko not_active Withdrawn
- 2021-06-03 BR BR112022024728A patent/BR112022024728A2/pt unknown
- 2021-06-03 US US18/007,714 patent/US20230270703A1/en active Pending
- 2021-06-03 IL IL298733A patent/IL298733A/en unknown
- 2021-06-03 WO PCT/US2021/035749 patent/WO2021247900A1/en not_active Ceased
- 2021-06-03 WO PCT/US2021/035750 patent/WO2021247901A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010125416A1 (en) | Drug delivery to the anterior and posterior segments of the eye | |
| KR20160147023A (ko) | 안 질환 및 장애 치료용 화합물 | |
| JP7730816B2 (ja) | 過剰血管新生に関連する眼疾患を治療する化合物 | |
| ZA200604403B (en) | Amelioration of macular degeneration and other ophthalmic diseases | |
| JP2008308489A (ja) | ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤 | |
| EP2990040B1 (en) | Therapeutic agent for eyeground disease | |
| WO2005030221A1 (ja) | 加齢黄斑変性治療剤 | |
| EP3808352A1 (en) | Use of salidroside and derivative thereof in preparation of inhibitor medicament for diseases of ophthalmic fibrosis caused by abnormalities of extracellular matrix proteins | |
| JP2018024677A (ja) | ラキニモドを使用する眼炎症性疾患の治療 | |
| JP6116714B2 (ja) | 眼科炎症疾患治療用点眼剤組成物及びその製造方法 | |
| JP7470791B2 (ja) | 眼疾患の予防または治療用点眼組成物 | |
| JP2023529845A5 (https=) | ||
| KR102860024B1 (ko) | 이나보글리플로진을 포함하는 안질환의 예방 또는 치료용 약학적 조성물 | |
| JP2018533631A (ja) | 網膜疾患の治療のためのミラベグロン | |
| EP0647445B1 (en) | Composition for prophylaxis and treatment of myopia | |
| CN100353947C (zh) | 以甾体为有效成分的视网膜和脉络膜疾病治疗剂 | |
| TWI918632B (zh) | 黃體激素組合 | |
| US20250134849A1 (en) | Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin | |
| TW201028176A (en) | Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye | |
| EP4676597A2 (en) | Ripasudil based ophthalmic treatments | |
| AU2023255001A1 (en) | Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin | |
| US6248759B1 (en) | Method for treatment of light-injured retinal degeneration disease | |
| CA3217868A1 (en) | Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin | |
| JP2002356431A (ja) | ステロイドを有効成分とする網脈絡膜疾患治療剤 | |
| WO2000076454A2 (en) | Therapeutic compositions for ophthalmic use and therapeutic compositions for brain central lesions |